Related Experiment Video
Updated: Jun 30, 2026
09:33
Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
Published on: March 20, 2018
Aflatoxin B1 formamidopyrimidine adducts in human hepatocarcinogenesis: a preliminary report
1Department of Laboratory Medicine, University of California, San Francisco.
Gastroenterology
|November 1, 1989
Summary
Aflatoxin-B1-formamidopyrimidine DNA adducts were detected in non-tumorous liver tissues but not in tumors. Individual DNA capacity to form these adducts varied significantly, suggesting a role in hepatocarcinogenesis.
Area of Science:
- Hepatology
- Toxicology
- Molecular Biology
Background:
- Aflatoxin-B1 is a potent carcinogen linked to liver cancer.
- Aflatoxin-B1-formamidopyrimidine is a persistent DNA adduct formed by aflatoxin-B1 exposure.
- Understanding the distribution and formation of these adducts is crucial for elucidating hepatocarcinogenesis.
Purpose of the Study:
- To investigate the in vivo presence of aflatoxin-B1-formamidopyrimidine DNA adducts in human hepatocellular carcinoma and nontumorous liver tissues.
- To assess in vitro aflatoxin-B1-formamidopyrimidine adduct formation in DNA from different liver tissue types and individuals.
- To evaluate the influence of hepatitis B virus (HBV) DNA integration on adduct formation.
Main Methods:
- Immunohistochemical analysis of 14 paired human liver tissue sections (tumorous and nontumorous) using a specific monoclonal antibody.
- Modified DNA immunoblot assay to measure in vitro adduct formation in cellular DNA.
- Comparison of adduct levels in DNA with and without integrated HBV DNA.
- Assessment of adduct formation in DNA from tumorous versus nontumorous tissues of the same individual.
- Evaluation of inter-individual variability in DNA's capacity for adduct formation.
Main Results:
- Aflatoxin-B1-formamidopyrimidine adducts were detected in nuclear and cytoplasmic compartments of 4 out of 14 nontumorous liver specimens.
- No adducts were found in any of the 14 tumorous liver tissues or in three normal control livers.
- In vitro studies showed no significant difference in adduct formation between DNA samples with or without integrated HBV DNA.
- No difference in adduct formation was observed between DNA from tumorous and nontumorous tissues of the same individual.
- Significant and reproducible inter-individual variations in the capacity of DNA to form aflatoxin-B1-formamidopyrimidine adducts were observed.
Conclusions:
- The findings suggest a potential differential distribution or repair of aflatoxin-B1-formamidopyrimidine adducts between nontumorous and tumorous liver tissues.
- The absence of adducts in tumorous tissues warrants further investigation into the molecular mechanisms of hepatocarcinogenesis.
- The observed inter-individual differences in DNA adduct formation capacity highlight potential genetic or epigenetic factors influencing susceptibility to aflatoxin-induced liver cancer.
- The developed DNA immunoblot assay is a valuable tool for future research on the role of aflatoxin-B1-formamidopyrimidine adducts in human hepatocarcinogenesis.
Related Concept Videos
01:26Physical Properties of Amines
Amines with low molecular weight are usually gaseous at room temperature, while those with high molecular weight are liquid or solids in nature. Usually, low molecular weight amines have a rotten fish-like smell. Diamines typically have a pungent smell. For instance, cadaverine and putrescine, depicted in Figure 1, are two molecules responsible for decaying tissue.
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:25Bioactivation and Tissue Toxicity
Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...